Gastrointestinal cancers encompass the esophagus, stomach, bowel and rectum, liver, and pancreas.

The Gastrointestinal Disease Site Group (GI- DSG) produces evidence-based reports to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. The titles of the reports produced to date by the GI DSG are listed below, together with links to the PDF versions of those reports.

Colorectal Cancer

• Preoperative or Postoperative Therapy for the Management of Patients with Stage II or III Rectal Cancer
  EBS #2-4: July 2008
  

  EBS #2-4 replaces Practice Guidelines #2-3 Postoperative Adjuvant Radiotherapy and/or Chemotherapy for Resected Stage II or III Rectal Cancer and #2-13 The Use of Preoperative Radiotherapy in the Management of Patients with Clinically Resectable Rectal Cancer.

  • Practice Guideline
    
  • Evidence-Based Series
• Management of Squamous Cell Cancer of the Anal Canal
  EBS #2-8: March 2009
  
  • Practice Guideline
    
  • Evidence-Based Series
• Follow-up of Patients with Curatively Resected Colorectal Cancer
  2-9 PG: January 2004 Update
  
  • Summary
  • Summary & Full Report
• Oral Capecitabine (XelodaTM) in the First-line Treatment of Metastatic Colorectal Cancer
  2-15 EBS: February 2005 Update
  
  • Practice Guideline
  • Evidence-based Series
• Use of Irinotecan in the Second-Line Treatment of Metastatic Colorectal Carcinoma
  2-16 PG: Update July 2004
  
  • Summary
  • Summary & Full Report
• Use of Irinotecan (Camptosar®, CPT-11) Combined with 5-Fluorouracil and Leucovorin (5FU/LV) as First-line Therapy for Metastatic Colorectal Cancer
  2-16b PG: February 2003 Update
  
  • Summary
  • Summary & Full Report
• Use of Raltitrexed (TomudexTM) in the Management of Metastatic Colorectal Carcinoma
  2-17 PG: February 2005 Update
  
  • Summary
  • Summary & Full Report
• The Role of Oxaliplatin Combined with 5-Fluorouracil and Folinic Acid in the First and Second-Line Treatment of Advanced Colorectal Cancer
  2-22 EBS: December 2006
  
  • Practice Guideline
  • Evidence-based Series
• The Role of Bevacizumab (Avastin ^TM ) Combined with Chemotherapy in the Treatment of Patients With Advanced Colorectal Cancer
  2-25 EBS: May 2008
  
  • Practice Guideline
  • Evidence-based Series
• Adjuvant Systemic Chemotherapy for Stage II and III Colon Cancer Following Complete Resection
  2-29 EBS: April 2008
  EBS #2-29 replaces Practice Guidelines #2-1 Adjuvant Therapy for Stage II Colon Cancer Following Complete Resection and #2-2 Adjuvant Therapy for Stage III Colon Cancer Following Complete Resection
  
  • Practice Guideline
  • Evidence-based Series
  
  

Pancreatic Cancer

• The Treatment of Locally Advanced Pancreatic Cancer
  2-7 PG: February 2004 Update
  
  • Summary
  • Summary & Full Report
• Use of Gemcitabine in the Treatment of Advanced Pancreatic Adenocarcinoma
  2-10 PG: June 2005 Update
  
  • Summary
  • Summary & Full Report
• Chemotherapy or Radiotherapy for Resectable Pancreatic Adenocarcinoma
  2-23 EBS: November 2007
  
  • Practice Guideline
  • Evidence-based Series

Esophageal

• Preoperative or Postoperative Therapy for Resectable Esophageal Cancer
  2-11 EBS Version 2.2008: May 2008 Rewrite
  
  • Practice Guideline
  • Evidence-Based Series
  
  
• Combined Modality Radiotherapy and Chemotherapy in the Non-surgical Management of Localized Carcinoma of the Esophagus
  2-12 PG: February 2005
  
  • Summary
  • Summary & Full Report

Gastric

• Systemic Therapy for Advanced Gastric Cancer
  2-26 EBS: June 29, 2010
  Section 2 has been submitted for journal publication and is not presently available.
  
• Summary
• Summary & Full Report
  
  
• Neoadjuvant or Adjuvant Therapy for Resectable Gastric Cancer
  2-14 PG Version 2.2000: May 2003 Update
  EBS #2-14 is scheduled to be updated in 2009.
  • Summary
  • Summary & Full Report